Hybrid Ablation Research Articles

Strategic timing- early and delayed catheter ablation in atrial fibrillation

Abstract Background Atrial fibrillation (AF) is the most common sustained arrhythmia. AF catheter ablation (CA) is superior to antiarrhythmic drug (AAD) therapy in maintaining sinus rhythm. However, not much is known regarding the optimal timing of the ablation. Purpose This review aims to examine the evidence supporting both early and delayed ablation approaches, as well as explore their respective disadvantages. Methods We performed an electronic search in databases such as PubMed, ScienceDirect, Springer, Wiley Online Library, focusing on studies published from 2013 until 2022 and including both observational studies and randomized controlled trials (RCTs). Left atrial diameter and ejection fraction (EF) were assessed. The limit between early and delayed ablation was set to be 3 years, considering delayed CA studies with a diagnosis-to-ablation-time (DAT) of 3 years or more, and early CA studies with a DAT of less than 3 years. Included studies were selected according to our eligibility criteria: observational studies or RCTs that included patients with symptomatic paroxysmal or persistent AF that underwent ablation using either radiofrequency or cryoballoon approach or both approaches, studies that reported DAT, studies that included a follow-up period, studies that evaluated AF recurrence or AF burden. Studies that included a surgical ablation, a hybrid ablation approach, or ablation for arrhythmias other than AF were excluded. Results Ten studies were selected out of 1387 identified records. After a follow-up period of 1 year, the early ablation subgroup had a lower mean AF recurrence rate (31.1%) compared to that of the delayed ablation subgroup (37.7%) ( p<0.0004). The median AF recurrence rate in radiofrequency ablation group was (47.8%) in comparison to the AF recurrence rate in cryoablation group which was (27.4%) (p<0.0001). In studies that included paroxysmal AF patients exclusively, the AF recurrence rate was directly proportional to the DAT(R=0.95). Conclusion Our results demonstrate that DAT correlates with recurrence rate at 1 year following AF CA, the shorter the DAT the better the outcome especially in paroxysmal AF population.Prisma study selection flow diagramCorrelation between DAT-AF recurrence

Hybrid versus catheter ablation for Hypertrophic CardioMyopathy with Atrial Fibrillation (HCM-AF): study protocol for a randomised controlled trial

IntroductionAtrial fibrillation (AF) is an independent predictor of adverse outcomes in patients with hypertrophic cardiomyopathy (HCM). Although catheter ablation is highly recommended for general AF populations, it is less effective...

Outcomes of hybrid surgical ablation and concomitant left atrial appendage exclusion in long-standing persistent atrial fibrillation.

Management of patients with long-standing persistent atrial fibrillation (LSPAF) presents a clinical challenge. Hybrid convergent ablation has been shown to have superior efficacy compared to endocardial-only ablation. However, data on concomitant left atrial appendage (LAA) management along with hybrid ablation is sparse. We aimed to evaluate the effectiveness of concomitant hybrid convergent ablation and LAA clipping in patients with LSPAF. We conducted a retrospective analysis of all patients with LSPAF who underwent hybrid surgical ablation with LAA clipping at our institution. The primary endpoint was a recurrence of atrial arrhythmias at 12 months. Further, the durability of surgical left atrial posterior wall ablation was examined during the endocardial catheter ablation using standing electrophysiological criteria. A total of 79 patients were included. Mean age was 63.5 ± 9.6 years, and 71% were males. LAA clipping was performed in 99% of patients. The mean time between the surgical and endocardial stages of the procedure was 2.6 ± 1.7 months. Persistent posterior wall activity was observed in 34.2% (n = 27/79) patients during the endocardial phase of the procedure. Cardiac implantable electronic device was used in 74% of patients for monitoring of recurrence of atrial fibrillation (AF). The primary effectiveness of AF freedom at 12 months was 73.8% (45/61). Over a 12-month follow-up period, 11.4% (9/79) of patients required repeat catheter ablation, of which 88.9% (8/9) had evidence of persistent posterior wall activity. Concomitant hybrid convergent ablation and LAA exclusion with an atrial clip provides reasonable long-term AF-free survival in patients with LSPAF. Persistent posterior wall activity is seen commonly in patients presenting with recurrent AF following hybrid convergent AF ablation.

TCT-536 Impact of Hybrid Ablation and Surgical Closure of the Left Atrial Appendage on the Flow in the Left Atrium

TCT-536 Impact of Hybrid Ablation and Surgical Closure of the Left Atrial Appendage on the Flow in the Left Atrium

Short- and long-term outcomes in isolated vs. hybrid thoracoscopic ablation in patients with atrial fibrillation: a systematic review and reconstructed individual patient data meta-analysis.

Both isolated thoracoscopic and hybrid thoracoscopic atrial fibrillation (AF) ablation techniques have demonstrated favourable outcomes in the management of patients with (long-standing) persistent AF, as compared with catheter ablation. However, it is currently unknown whether there is a difference in short- and long-term outcomes when comparing these two minimally invasive surgical AF ablation procedures. Therefore, a systematic review and meta-analysis were performed to investigate these two techniques, with a specific emphasis on long-term freedom from atrial tachyarrhythmias (ATAs). A systematic search through PubMed, EMBASE, and the Cochrane Library databases was performed. All studies reporting on short-term outcomes were included in the meta-analysis. A pooled analysis of long-term freedom from ATA was performed based on Kaplan-Meier (KM) curve-derived individual patient data. Reconstructed individual time-to-event data were analysed in a multivariable Cox frailty model with adjustments for age, sex, type of AF, duration of AF history, and study variable (frailty term in the frailty Cox model). In total, 53 studies were included in the meta-analysis, encompassing 4950 patients. There were no differences in major short-term outcomes (mortality or stroke) between isolated thoracoscopic and hybrid thoracoscopic ablation. A total of 18 studies reported KM curves for long-term freedom from ATA, comprising 2038 patients. Adjusted analysis revealed that hybrid ablation was significantly associated with greater freedom from ATA [adjusted hazard ratio (aHR) = 0.59, 95% confidence interval (CI): 0.43-0.83, P < 0.001] compared with isolated thoracoscopic ablation. Additionally, older age (aHR = 1.07, 95% CI: 1.03-1.12, P = 0.002) and a higher percentage of male patients (aHR = 1.02, 95% CI: 1.01-1.03, P < 0.001) were significantly associated with lower long-term freedom from ATA recurrence. Hybrid thoracoscopic AF ablation is associated with a greater long-term freedom from ATA when compared with isolated thoracoscopic ablation, without differences in complications.

Comparing simultaneous hybrid ablation with stand-alone thoracoscopic surgical ablation for the treatment of non-paroxysmal atrial fibrillation: a prospective randomized controlled trial.

Advanced atrial fibrillation (AF) is currently a dilemma for electrophysiologists when choosing a minimally invasive treatment strategy. Previous studies have demonstrated the outcome of either catheter ablation or thoracoscopic surgical ablation (SA) is unsatisfactory in these patients. Whether hybrid ablation (HA) could improve outcomes in these patients is unknown. The purpose of this study was to evaluate the clinical efficacy of HA for the treatment of advanced AF. A randomized controlled trial was designed to enrol patients with persistent AF (PerAF) and enlarged left atrium or long-standing persistent AF (LSPAF) who were randomized to HA or thoracoscopic SA at a 1:1 ratio. The primary endpoint was freedom from any recurrence of AF off antiarrhythmic drugs (AADs) 12 months after operation. The primary endpoint was monitored by 7-day electrocardiogram monitoring devices. One hundred patients were enrolled. The mean age was 58.5 ± 7.6 years, and the mean left atrial diameter (LAD) was 50.1 ± 6.1 mm. At 12 months, freedom from AF off AADs was recorded in 71.4% (35/49) of patients in HA group and 45.8% (22/48) in SA group [odds ratio 2.955, 95% confidence interval (1.275-6.848), P = 0.014]. HA significantly reduced patients' AF burden (30.2% in SA group and 14.8% in HA group, P = 0.048) and the LAD (mean differences: -5.53 ± 4.97 mm in HA group and -3.27 ± 5.20 mm in SA group, P = 0.037) at 12 months after operation. In patients with PerAF and enlarged left atrium or LSPAF, HA achieved better freedom from AF after 1 year of follow-up compared with thoracoscopic SA.

Narrative Review: Surgical and Hybrid Management of Atrial Fibrillation.

Although significant strides have been made in non-pharmacologic management of atrial fibrillation (AF), these treatments remain a work in progress. While catheter ablation is often effective for management of paroxysmal AF, it is less successful in patients with persistent or longstanding persistent AF. This review was undertaken to clarify the risks, benefits, and alternatives to catheter ablation for non-pharmacologic AF management. In order to clarify the roles of surgical and hybrid ablation, this narrative review was undertaken by searching MEDLINE to identify peer-reviewed clinical trials, randomized controlled trials, meta-analyses, review articles, and other clinically relevant studies. The search was limited to English-language reports published between 1960 and 2023. Atrial fibrillation was searched using the terms surgical ablation, catheter ablation, hybrid ablation, stroke prevention, left atrial occlusion, and atrial excision. Google and Google Scholar, as well as bibliographies of identified articles, were also reviewed for additional references. The Cox-maze surgical approach is still the most efficacious non-pharmacological treatment for AF. Hybrid ablation, combining cardiac surgical and catheter ablation techniques, has become an attractive option for persistent or longstanding persistent AF.

Long-term outcomes in hybrid versus standalone thoracoscopic ablation in patients with atrial fibrillation: a systematic review and reconstructed individual patient data meta-analysis

Abstract Background Both hybrid and standalone thoracoscopic atrial fibrillation (AF) ablation techniques have demonstrated favorable outcomes in the management of (long-standing) persistent AF patients, as compared to catheter ablation. However, it is currently unknown whether there is a difference in long-term freedom from AF when comparing these two procedures. Purpose To compare long-term freedom from atrial tachyarrhythmias (ATA) in patients undergoing hybrid and standalone thoracoscopic AF ablation. Methods A systematic search encompassing PubMed, EMBASE, and the Cochrane Library databases from January 1, 2012, to September 6, 2023, was performed using the following search terms: 'thoracoscopic ablation,' 'hybrid ablation,' 'atrial fibrillation,' and various alternative spellings. Articles were included for pooled analysis of freedom from ATA after meeting the criteria of reporting on consecutive patients and presenting Kaplan-Meier (KM) curves. Individual time-to-event data were reconstructed from the KM curves and included in a multivariable Cox and frailty Cox model with adjustments for age, sex, type of AF, AF duration, and study (frailty term in the frailty Cox model). Results In total, 18 studies were included in the meta-analysis for long-term freedom from ATA, comprising 2215 patients. Patients undergoing hybrid thoracoscopic ablation were older (62.0 vs. 58.8 years old, p=0.046), had less frequently paroxysmal AF-history (9.6% vs. 32.1%, p&amp;lt;0.01), and had a longer duration of AF-history (7.0 vs. 5.3 years, p=0.04), as compared to patients undergoing standalone thoracoscopic ablation. There were no significant differences between the two ablation procedures regarding short-term outcomes including early mortality (0.6% vs. 1.0%, p=0.07) and early stroke (1.9% vs 0.9%, p=0.11). Adjusted analysis revealed that hybrid thoracoscopic ablation was significantly associated with greater freedom from ATA (Hazard Ratio [HR]=0.59, 95%CI: 0.43-0.83, p&amp;lt;0.001) compared to standalone thoracoscopic ablation (see Figure 1A). Additionally, older age (HR=1.07, 95%CI: 1.03-1.12, p=0.002) and a higher percentage of male patients (HR=1.02, 95% CI: 1.01-1.03, p&amp;lt;0.001) were significantly associated with ATA recurrence. Adjusted freedom from ATA at 1 year, 3 years, and 5 years was 71.6%, 55.1%, and 46.8% for thoracoscopic ablation, and 82.0%, 69.9%, and 63.6% for hybrid ablation (see Figure 1B). Conclusion Hybrid thoracoscopic AF-ablation is associated with a higher level of freedom from ATA when compared to standalone thoracoscopic ablation.Figure 1

Hybrid ablation versus repeated catheter ablation in persistent atrial fibrillation: long-term results of the HARTCAP-AF trial

Abstract Background The HARTCAP-AF study compared the efficacy and safety outcomes in forty-one ablation-naive patients with persistent atrial fibrillation (AF) randomized to thoracoscopic hybrid ablation (HA) or stand-alone catheter ablation (CA). One-year results have shown that thoracoscopic HA has superior rhythm outcomes than CA, without increasing complications. Purpose Here, we evaluated the efficacy, safety and quality of life (QOL) of thoracoscopic HA and CA within a long-term follow-up (FU) duration of three years. Methods Efficacy outcomes included freedom from atrial tachyarrhythmia (ATA) recurrences ≥5 minutes off and allowing antiarrhythmic drugs (AAD) after 24 and 36 months. Safety outcomes, including serious adverse events (SAEs), and QOL, measured by the EHRA AF symptom score, were evaluated after 36 months. Results After a mean FU duration of 25±3 and 38±3 months, freedom from ATA recurrences was higher in the HA group compared to the CA group off AAD (68.4% vs. 22.7%, P=0.002 and 57.0% vs. 22.7%, P=0.005) and allowing AAD (73.7% vs. 22.7%, P=0.001 and 63.2% vs. 22.7%, P=0.001) (Figure 1, Table 1). The number of redo catheter procedures was higher in the CA arm than the HA arm (n=15 vs. n=3, P=0.021). The total number of SAEs was low and did not differ between groups (HA: n=6 vs. CA: n=7, P=0.989). Moreover, QOL measured by the EHRA AF-symptom score improved for both groups post-procedure (3.2±0.7 and 1.6±0.78, P&amp;lt;0.001) and were better for HA than CA after 3 years (1.3±0.7 and 1.9±0.8, P=0.029). Conclusion After three years, (thoracoscopic) HA continues to have superior rhythm outcomes compared to CA with a comparable long-term safety profile. While both procedures resulted in a reduction in AF symptoms, EHRA scores were more favorably scored by patients in the HA arm. Therefore, in experienced centers thoracoscopic HA should be considered as a first-line treatment to percutaneous approaches for ablation-naive patients with persistent AF.Figure 1Table 1

A propensity score matched comparison of pulsed field versus hybrid ablation in patients with long standing persistent atrial fibrillation

Abstract Introduction On one hand pulsed-field ablation (PFA) has shown favourable data in terms of safety and efficiency for pulmonary veins isolation (PVI). One the other hand, hybrid ablation results in better outcomes in patients with persistent atrial fibrillation (AF), as it combines a thoracoscopic epicardial and transvenous endocardial approach in a single procedure. Purpose Aim of this study was to to compare 1-year follow-up data of patients with long standing persistent AF undergoing PVI and posterior wall isolation using PFA, and hybrid AF ablation. Methods Consecutive patients with long standing persistent AF undergoing a first PVI with PFA at our institution were included. For comparison, patients with long standing persistent AF undergoing a first PVI with hybrid ablation were selected using a 1:1 nearest neighbor propensity score matching. Hybrid AF ablation was performed in a one-step procedure: (i) thoracoscopic ablation followed by (ii) endocardial mapping and eventual ablation. All patients received PVI and posterior wall isolation in both group. Additional lesions were performed based on clinical indication and physician judgement. The primary endpoint was recurrence of atrial tachyarrhythmia after 12 months of follow-up (with a blanking period of 3 months). Results A total of 130 patients with persistent AF underwent hybrid ablation and 72 patients underwent PFA. 85 patients (age:67.5±9.7 years, 68.2% males, CHA2DS2-VASc: 2.5±1.3) with long standing persistent AF underwent their first AF ablation (PFA N= 39; Hybrid N = 46). After a 1-year follow-up, freedom from atrial tachyarrhythmia recurrence was 74.4% with PFA and 71.7% with hybrid ablation (p = 0.786). After propensity score matching, a total of 39 matched pairs of PFA and hybrid first AF ablation remained. The result remained unchanged and no significant difference was observed between treatment cohorts after matching (Figure 1, p=0.039). Conclusion In a propensity score matched analysis of patients with long standing persistent AF, freedom from any atrial tachyarrhythmia 1 year after AF ablation using PFA was favourable and at least as good as with hybrid ablation.

Two-year safety and effectiveness of hybrid ablation versus catheter ablation in patients with non-paroxysmal AF: mid-term results of the CEASE-AF trial

Abstract Background Hybrid Ablation for atrial fibrillation (AF) combines epicardial and endocardial ablation through a Heart Team approach to target durable, transmural isolation of the pulmonary veins (PV) and left atrial posterior wall (LAPW). While the primary efficacy endpoint at 12 months was met with a significant benefit increase for hybrid ablation, we now report the midterm durability of those results. Purpose To evaluate 24-months safety and effectiveness of Hybrid Ablation with left atrial appendage exclusion (LAAE) versus Catheter Ablation in patients with persistent AF/enlarged left atrium and longstanding persistent AF (LSPAF). Methods CEASE-AF is a prospective, multi-center, 2:1 randomized controlled trial. Eligible patients were 18-75 years of age, had symptomatic, drug-refractory persistent AF and enlarged left atrium (&amp;gt;4 cm) or LSPAF, and were undergoing a first ablation. Hybrid Ablation consisted of two stages: thoracoscopic epicardial radiofrequency (RF) ablation for PV and LAPW isolation and epicardial LAAE followed by endocardial ablation 91-180 days later. Catheter Ablation consisted of minimum PV isolation by endocardial RF ablation, and repeat ablation was allowed between 91-180 days. In both arms, additional lesions were permitted according to institutional practices. Effectiveness was freedom from AF/atrial flutter (AFL)/atrial tachycardia (AT) off anti-arrhythmic drugs (AAD) (except AADs not exceeding doses which previously failed) and was assessed through 48-h Holter monitoring reviewed by an independent core laboratory blinded to the study. Safety was major adverse events throughout the study, adjudicated by an independent Clinical Events Committee. Results There were 102 Hybrid Ablation and 52 Catheter Ablation patients; 26% were female, mean age was 60.7±7.9 years, mean LAD was 4.7±0.4 cm, and 19% had LSPAF with no differences between arms. The 12- and 24-month results are shown for comparison (Table). Through 24-months, effectiveness was 66.3% (63/95) in the Hybrid Arm and 33.3% (17/51) in the Catheter Arm (absolute difference 33.0% [95% CI 14.3%, 48.3%; p&amp;lt;0.001]). Major adverse event rates through 24-months were statistically similar at 10.8% (11/102) in the Hybrid Arm and 9.6% (5/52) in the Catheter Arm (p=1.0). Through 24-months, repeat ablations were performed in 7.4% (7/95) of the Hybrid Arm versus 37.3% (19/51) of the Catheter Arm (p&amp;lt;0.001), and cardioversions were performed in 14.7% (14/95) of the Hybrid Arm versus 29.4% (15/51) of the Catheter Arm (p=0.034) Conclusions: CEASE-AF demonstrated that superior effectiveness of Hybrid Ablation including LAAE versus Catheter Ablation was durable through 24-month follow-up, with 33% absolute improvement in freedom from AF/AFL/AT. Safety rates continued to be similar between arms. Three-year follow-up is ongoing.

The hybrid ablation approach to treating long-standing persistent atrial fibrillation: real-world data from a tertiary institution

Abstract Background Pulmonary vein isolation(PVI) is effective treatment for atrial fibrillation(AF) but efficacy of endocardial ablation-alone for long-standing persistent AF is limited(1). Hybrid AF ablation may offer better outcomes but studies were on patients with paroxysmal/persistent-AF(2) and relied on Holter-alone to assess recurrences(3). Our hybrid-AF ablation patients were all long-standing persistent cases and monitored with implantable loop recorders(ILR). Aim Evaluate long-term outcomes of hybrid-AF ablation using ILR data. Methods The hybrid approach at our institution consisted of a first-stage minimally invasive surgical epicardial ablation of the left atrial posterior wall via radiofrequency (RF) ablation. An ILR was implanted at the same setting. A few months later, the second-stage endocardial catheter ablation was performed to ensure PVI and ‘touch-up’ of any residual conduction gaps in the left atrium. All epicardial ablation cases were performed at the cardiothoracic operating-room in our tertiary hospital (‘hub’) whilst the endocardial RF-cases were performed at either the hub or satellite centre(‘spoke’) as part of our institution’s ‘hub-and-spoke’ model. Inclusion criteria for hybrid AF-ablation were long-standing persistent AF, body mass index (BMI) &amp;lt;40 and standard indications for AF ablation as per ESC 2020 AF guidelines(4). Once both aspects of the hybrid approach were completed, patients were followed up in ILR remote monitoring clinics. AF recurrence was defined as AF/atrial tachycardia(AT) lasting &amp;gt;30s. All data were obtained retrospectively via hospital electronic patient records. Results 38 consecutive patients completed both aspects of hybrid ablation between December 2017-August 2023 with mean follow up of 19±13months(mean±SD). Baseline data, procedure characteristics and details of complications are shown in Table 1. ILR data was obtained in 36/38 patients(ILR implantation precluded in one due to previous breast cancer surgery. One had ILR battery depletion contributed by significant delay between the 2 stages of the hybrid ablation). AF/AT recurred in one third of patients during the blanking period(3 months) whilst 45% remained in sinus rhythm at 1-year; at 2yrs, 39% maintained SR and 25% at 3yrs (Figure 1). Post-hybrid ablation, two patients underwent re-do AF/AT ablation. The relatively high recurrence rate compared to other studies may be due to: very long duration of AF prior to hybrid-ablation(7.0±3.6years), significant delay between both stages of the procedure(9±11months) due to the pandemic and competing waiting list pressures, multiple comorbidities (82% had &amp;gt;2 comorbidities, 42% were obese) and the higher arrhythmia pickup rate with ILRs compared with intermittent rhythm monitoring. Conclusion Our study provides real world insight into the challenges of delivering a hybrid AF ablation service but highlights its utility in long-standing persistent AF patients.Table 1Figure 1

Acute and long-term lesion durability and reconnection patterns following hybrid atrial fibrillation ablation

Abstract Background/introduction Hybrid ablation (AF) is a well-established rhythm control strategy in non-paroxysmal AF patients and can be performed as a staged or one-step epicardial-endocardial approach. Data on need for endocardial touch-up acutely after epicardial ablation are limited, as well as long-term reconnection patterns in patients undergoing redo procedures. Purpose to evaluate the lesion transmurality detected via endocardial mapping acutely after epicardial radiofrequency (RF) ablation, as well as anatomical and clinical predictors of residual endocardial gaps in a large cohort of patients undergoing hybrid AF ablation. Furthermore, long-term lesion durability will be assessed in patients undergoing repeat endocardial ablation. Methods Hybrid procedures were performed in a one-step fashion (endocardial mapping +/- ablation immediately following left thoracoscopy epicardial ablation). Epicardial pulmonary vein (PV) isolation was achieved via a bipolar RF clamp; further epicardial linear ablation was performed with a RF bipolar linear device. Additional lesions were performed according to physician’s preference on a patient basis. At the end of the procedure, the left atrial appendage (LAA) was clipped. Results A total of 130 patients were included (mean age: 65±9.4; 72.3% males); among them, 19.2% and 55.4% had persistent or long-standing persistent AF. All patients received epicardial PV and posterior wall (PW) isolation plus additional RF applications to the LAA/posterolateral ridge. Other targets included the right inferior ganglionted plexus in 36.2% (n=47) and anterior mitral line (AML) in 3.8% (n=5). In 13.1% (n=17) epicardial lesions could not be completed due to difficult anatomy. At the end of the procedure, an attempt to clip the LAA was done in all patients, resulting in 97.7% success (3 LAA clip failures due to anatomical reasons). Acute endocardial mapping revealed a PV reconnection rate of 4.6% (n=24), left superior and right superior PVs being the veins most commonly reconnected (6.15% and 5.38%, respectively). PW and AML reconnections were documented in 8.5 % and 60% (3 out of 5 patients). Multivariate analysis showed left atrial (LA) volume and male gender as predictors for acute endocardial gaps after complete epicardial lesions. A redo procedure after first recurrence was performed in 24.6% (n=32), showing lesion durability of 100% for left PVs, 90.6% for right superior and 93.7% for right inferior PVs. PW remained isolated in 78.1% of patients. Age was a predictive factor for chronic gaps after recurrence. At a mean follow-up of 51±35 months, arrhythmia-free survival after multiple procedures was 68.5%. Conclusion In a large cohort of AF patients undergoing hybrid ablation,acute and chronic lesion durability was hight.LA volume and male gender were predictors of acute reconnection after epicardial ablation.

Left atrial appendage clipping during hybrid atrial fibrillation ablation: a very long-term, single-center experience

Abstract Background/introduction Epicardial left atrial appendage (LAA) clipping is an effective strategy for stroke prophylaxis in high thromboembolic (TE) and bleeding risk patients with atrial fibrillation (AF). In addition to LAA exclusion from systemic circulation, clipping promotes concomitant appendage isolation, which might have positive impacts on arrhythmia control. Purpose The aim of this study was to report safety, success rate, and the long-term clinical outcomes of LAA clipping in a large cohort of AF patients undergoing concomitant hybrid ablation. Methods Consecutive patients undergoing hybrid AF ablation between 2013 and 2023 were enrolled. Hybrid ablation was performed in a one-step procedure consisting of thoracoscopic epicardial radiofrequency (RF) ablation followed by endocardial mapping and ablation, if needed. Ablation lesion set included pulmonary vein (PV) and posterior wall (PW) isolation, as well as RF applications to the LAA/posterolateral ridge. LAA clipping was performed via Atriclip exclusion system (Atricure, Inc., The Nederlands) after epicardial ablation. Additional endocardial lesions were performed in case of incomplete epicardial ablation or at physician’s discretion. Results A total of 130 patients were included (mean age: 65±9.4; 72.3% males); among them, 19.2% and 55.4% had persistent or long-standing persistent AF, respectively. Mean CHA2DS2-VASC and HAS-BLED were 3.1±1.1 and 2.3+-0.5. Five patients (3.8 %) had absolute contraindication to long-term oral anticoagulation, 3 (2.3%) had previous life-threatening bleeding events, 17 (13.1%) had a previous TE event. The final clip size was 35mm in 90.7% cases. Acute success was achieved in 97.7%; failure was due to LAA size (n=1), proximity to phrenic nerve (n=1), or bypass graft (n=1). One patient had incomplete occlusion due to a large secondary lobe, which required a second clip. No periprocedural complications related to clipping were documented. At a mean follow-up of 51±35 months, one (0.8%) patient had a stroke and 3 (2.3%) a transient ischemic attack (4 events per 552 patient/years; 0.7%). One patient had a microreentrant tachycardia mapped from the area near the LAA clipping. Conclusion In a large cohort undergoing hybrid AF ablation, epicardial LAA clipping was safe and highly successful. Acute failure was rare and due to LAA morphology or proximity to phrenic nerve and bypass graft. Thromboembolic event rate was very low.

Procedural characteristics, details on epicardial mapping-based lesion transmurality, and long-term success of posterior wall isolation with a pentaspline pulsed field ablation device

Abstract Background Achieving durable posterior wall isolation (PWI) with thermal-based energies is challenging, as reconnection rates have been reported to be up to 60%. Additionally, PWI can significantly increase the risk of collateral thermal damage to the esophagus. Pulsed field ablation (PFA) is a non-thermal energy source with a remarkable safety profile due to its selectivity to cardiac tissue. Additionally, PWI durability was reported to be 100% in a recent phase-3 study enrolling persistent AF patients undergoing PFA via the FarapulseTM system. Purpose To report procedural details, acute lesion transmurality, and long-term success of PWI via the FarapulseTMsystem. Methods Consecutive persistent AF patients undergoing first-time ablation with the FarapulseTM system at four different centres were prospectively enrolled. All patients received first-time pulmonary vein isolation (PVI) and PWI. PFA was performed with either a 31mm or a 35mm device and an energy output of 2.0kV. At least 2 applications per position were delivered. Primary efficacy endpoint was freedom from any atrial tachyarrhythmia &amp;gt;30s after a 3month blanking period. PW lesion transmurality was assessed in a subpopulation of patients with an indication for hybrid AF ablation and left atrial appendage (LAA) clipping. The procedure was performed according to the following steps: 1) endocardial PVI plus PWI via the FarapulseTM system; 2) endocardial high-density mapping with RhythmiaTM plus Intellanav OrionTM; 3) thoracoscopy-assisted epicardial high-density mapping with Intellanav OrionTM 4) left atrial appendage clipping. Results 157 persistent AF patients (mean age: 62±11years; 75.5% males) were included. First-pass PVI was achieved in 100% of patients. On average, pulsed electric field applications for PWI were 16.3±2.4. Mean procedural time was 66±17min; left atrial dwelling and fluoroscopy times were 46±12min and 14±6min, respectively. SR restoration during PWI was observed in 8 (5.1%) cases. Minor and major periprocedural complications occurred in 2.5% (groin hematoma: 4pts) and 0.6% (diplopia with negative cerebral MRI) patients, respectively. During a mean follow-up of 353±58 days, arrhythmia-free survival was 78.3% (n=123). A redo ablation was performed in 23 patients, showing reconnection of 22.8% of PVs. Durable PWI was observed in 82.6% of patients. In the subpopulation of patients (n=3) undergoing hybrid ablation plus LAA clipping, thoracoscopy-guided epicardial mapping of the PW was performed between 57 and 72 minutes after the last endocardial PFA application. All patients showed transmural PWI (Figure1). Conclusions In a real-world multicenter registry, PWI by means of the FarapulseTM system was safe and feasible, contributing to approximately 80% success rate after 1 year. Endocardial PFA-based PWI led to 100% transmural lesions acutely, with a rate of reconnection &amp;lt;20% at redo procedures.

Pulmonary Vein Isolation for Atrial Fibrillation: Comparison of a Very High-Power Very Short-Duration (vHPvSD) Ablation Protocol versus a Hybrid Ablation Approach-Procedural and Mid-Term Outcome Data.

Background: Pulmonary vein isolation (PVI) using radiofrequency ablation (RFA) is a standard-of-care treatment in the rhythm control strategy of symptomatic atrial fibrillation (AF). Ablation protocols, varying in the power and duration of energy delivery, have changed rapidly in recent years. Very high-power very short-duration ablation (vHPvSD) is expected to shorten procedural times compared to conventional ablation approaches. However, the existing data suggest that this might come at the cost of lower first-pass isolation rates, a predictor of poor ablation long-term outcomes. This study aims to compare a vHPvSD protocol to a hybrid strategy, in which the power and duration of the energy transfer are adapted depending on the anatomical location. Methods: We retrospectively analyzed procedural and outcome data from 93 patients (55 vHPvSD vs. 38 hybrid) scheduled for de novo pulmonary vein isolation. A vHPvSD ablation protocol (90 Watt (W), 4 s) was compared to a hybrid protocol using vHPvSD on the posterior wall and 50 W HPSD (high-power short-duration) ablation guided by the Ablation Index along the remaining spots. Results: Ablation times were significantly shorter in the vHPvSD cohort (5.4 min. vs. 14.2 min, p < 0.001), thus resulting in a significant reduction in the overall procedural duration (91 min vs. 106 min, p = 0.003). The non-significant slightly higher first-pass isolation rates in the vHPvSD cohort (85% vs. 76%, p = 0.262) did not affect freedom from AF 6 months after the procedure (83% vs. 87%, p = 0.622). Conclusions: vHPvSD helps in shortening the PVI procedural duration, thus neither affecting first-pass isolation rates nor freedom from atrial tachyarrhythmia recurrence at 6 months after the index procedure.

Isolated right-sided pericardial effusion following hybrid ablation for long-standing atrial fibrillation.

Isolated right-sided pericardial effusion following hybrid ablation for long-standing atrial fibrillation.

A novel sinus node-sparing hybrid ablation approach for inappropriate sinus tachycardia

A novel sinus node-sparing hybrid ablation approach for inappropriate sinus tachycardia

Concurrent vs Staged Hybrid Ablation for Long-Standing Persistent Atrial Fibrillation: A Propensity-Matched Cohort Study

BackgroundLong-term success rates of catheter ablation (CA) for long-standing persistent atrial fibrillation (LSPAF) are less than satisfactory. Further improvement of ablation methods is crucial for enhancing the treatment of LSPAF. ObjectivesThis study sought to compare the outcomes of concurrent vs staged minimally invasive surgical–catheter hybrid ablation for LSPAF. MethodsFrom December 2015 to December 2021, 104 matched patients (concurrent and staged, 1:1) were included in study. In the concurrent group, both left unilateral thoracoscopic epicardial ablation (EA) and CA were performed simultaneously in one procedure. In the staged group, EA was performed at the first hospitalization. If the patients experienced atrial fibrillation (AF) recurrence, CA was performed between 3 months and 1 year after EA. ResultsIn the concurrent group, 4 patients were restored to sinus rhythm after EA, and 41 were patients restored to sinus rhythm during CA; 86.5% (45 of 52) achieved intraprocedural AF termination during concurrent hybrid ablation. In the staged group, all 52 patients underwent staged CA because of the recurrence of AF or atrial tachycardia (AT). Forty-seven (90.4%) patients achieved intraprocedural AF or AT termination during CA. Freedom from AF or AT off antiarrhythmic drugs at 2 years after hybrid ablation was 79.9% ± 5.7% in the concurrent group and 86.0% ± 4.9% in the staged group (P = 0.390). Failure of intraprocedural AF termination (HR: 14.378) was an independent risk factor for AF recurrence after hybrid ablation. ConclusionsBoth concurrent and staged hybrid ablation could be safely and effectively applied to treat LSPAF. Improving the intraprocedural AF termination rate predicted better outcomes.

Left atrial function of patients with atrial fibrillation undergoing thoracoscopic hybrid ablation.

Thoracoscopic hybrid ablation is an effective and safe rhythm control strategy for patients with complex forms of atrial fibrillation. Its effect on left atrial function has not yet been studied. In a retrospective single-centre analysis of patients undergoing thoracoscopic hybrid ablation, the left atrial emptying fraction was calculated using the biplane modified Simpson method in the apical 2- and 4-chamber views on transthoracic echocardiography. Left atrial strain (reservoir, conduction and contractility) was quantified using dedicated software. Sixty-seven patients were included (mean age 64 years, long-standing persistent atrial fibrillation in 69%, median atrial fibrillation history duration 64 months). At baseline, left atrial function and contractility were poor. The reservoir and contractile strain improved postprocedure compared to baseline [15 (standard deviation (SD): 8) and 17 (SD: 6); P = 0.013; 3 (SD: 5) and 4 (SD: 4), P = 0.008], whereas the left atrial volume indexed to the body surface area was reduced [51 ml/m2 (SD: 14) and 47 ml/m2 (SD: 18), P = 0.0024]. In patients with preoperative (long-standing) persistent atrial fibrillation and in patients with rhythm restoration, improvements in the emptying fraction, (reservoir and contractile) strain and the left ventricular ejection fraction were observed, whereas the left atrial volume decreased (P < 0.05). In this cohort of patients with severely diseased left atria, improvement in left atrial contractility and in the emptying fraction after thoracoscopic hybrid ablation for atrial fibrillation in patients with persistent atrial fibrillation is mainly due to rhythm restoration. Interestingly, the procedure itself also results in improved left atrial reservoir strain and reversed left atrial remodelling by reducing left atrial volume.